抗毒蕈碱3受体抗体与系统性硬化症患者严重临床表型相关
在132例以胃肠道症状为主的系统性硬化症患者中,用ELISA检测抗M3R抗体,按抗体滴度最高四分位预设高滴度;高滴度者更常有弥漫型病变、高胃肠道严重度及抗RNPC3、抗U1RNP抗体,多变量分析示高胃肠道严重度与抗U1RNP抗体仍与高滴度抗M3R抗体相关。
要点
- 高滴度抗M3R抗体患者更常见弥漫型病变(43.8% vs 22.9%,P = 0.023)与高胃肠道严重度(90.9% vs 69.7%,P = 0.019)。
- 全肠道传输研究和UCLA GIT 2.0评分在有无高滴度抗M3R抗体两组间无差异。
- 多变量分析中高胃肠道严重度(OR 4.50,95%CI 1.11–18.18,P = 0.035)与抗U1RNP抗体(OR 20.36,95%CI 3.16–131.14,P = 0.002)与高滴度抗M3R抗体相关。
核心结论
- 抗M3R抗体与系统性硬化症患者更严重的胃肠道表型及独特的肠外和血清学特征相关。
- 作者认为利用这些特征可能有助于临床实践中优化风险分层,并为临床试验识别可能出现进展性胃肠道疾病的患者。
研究设计与样本
- 在132例以胃肠道症状富集的系统性硬化症患者队列中,用ELISA检测抗M3R抗体,按抗M3R滴度最高四分位预设高滴度以增强特异性。
- 比较有无高滴度抗M3R抗体患者的临床特征,包括高胃肠道严重度(Medsger胃肠道严重度评分≥2)、全肠道传输研究数据及UCLA硬皮病临床试验联盟胃肠道量表2.0(UCLA GIT 2.0)评分。
主要发现
- 132例中52例(39.4%)抗M3R抗体阳性,33例(25%)为高滴度抗M3R抗体。
- 与无高滴度者相比,高滴度患者更常有弥漫型病变(43.8% vs 22.9%,P = 0.023)、高胃肠道严重度(90.9% vs 69.7%,P = 0.019)、抗RNPC3抗体(18.2% vs 6.1%,P = 0.036)及抗U1RNP抗体(21.2% vs 2.0%,P = 0.001)。
- 全肠道传输研究与UCLA GIT 2.0评分在两组间无差异。
- 多变量logistic回归分析中,高胃肠道严重度(比值比4.50,95%CI 1.11–18.18,P = 0.035)与抗U1RNP抗体(比值比20.36,95%CI 3.16–131.14,P = 0.002)仍与高滴度抗M3R抗体相关。
关键数值与推荐
- 高滴度抗M3R抗体定义为抗M3R滴度最高四分位,系预先设定。
- 高胃肠道严重度定义为Medsger胃肠道严重度评分≥2。
临床怎么用
- 作者认为利用高滴度抗M3R抗体相关特征可能有助于临床实践中优化风险分层,并为临床试验识别可能出现进展性胃肠道疾病的患者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Functional antibodies play a role in SSc gastrointestinal (GI) disease, but their clinical relevance is unclear. We examined GI and extraintestinal features associated with anti-muscarinic-3 receptor (M3R) antibodies in SSc patients. METHODS: In a cohort enriched for GI symptoms, SSc patients were tested for anti-M3R antibodies using an ELISA. High-titres were defined a priori based on the top quartile of anti-M3R titres to enhance specificity. Clinical features, including high GI severity (Medsger GI Severity Score of ≥2), whole-gut transit study data and UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 (UCLA GIT 2.0) scores, were compared between patients with and without high-titre anti-M3R antibodies. RESULTS: In 132 patients, 52 (39.4%) tested positive for anti-M3R antibodies and 33 (25%) had high-titre anti-M3R antibodies. Compared with patients without high titres, high-titre patients were more likely to have diffuse disease (43.8% vs 22.9%, P = 0.023), high GI severity (90.9% vs 69.7%, P = 0.019), and anti-RNPC3 (18.2% vs 6.1%, P = 0.036) and anti-U1RNP antibodies (21.2 vs 2.0%, P = 0.001). Whole-gut transit studies and UCLA GIT 2.0 scores were not different between the groups. In multivariable logistic regression analysis, high GI severity [odds ratio: 4.50 (95% CI: 1.11, 18.18), P = 0.035] and anti-U1RNP antibodies [odds ratio: 20.36 (95% CI: 3.16, 131.14), P = 0.002] remained associated with high-titre anti-M3R antibodies. CONCLUSION: Anti-M3R antibodies are associated with a more severe GI phenotype and distinct extraintestinal and serological features in SSc patients. Utilizing these features may optimize risk stratification in clinical practice and identify those likely to have progressive GI disease for clinical trials.
引用
- Ayla AY, Kalavar NR, Pimentel M, et al. Anti-muscarinic 3 antibodies associate with a severe clinical phenotype in patients with systemic sclerosis. Rheumatology (Oxford). 2025. PMID: 40220335. doi:10.1093/rheumatology/keaf197
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。